A live and achieved webcast of the Company’s presentation at the Leerink Partners Global Biopharma Conference can be accessed under "Events & Presentations" in the Investor Relations section of the ...

Intra-Cellular Therapies (NASDAQ:ITCI) underwent analysis by 6 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table summarizes their recent ...

Advances Company’s industry-leading portfolio in mental health with addition of CAPLYTA ® (lumateperone), the first and only U.S. FDA-approved treatment for bipolar I and II depression as an ...

Intra-Cellular Therapies Inc. has identified phosphodiesterase PDE1 inhibitors reported to be useful for the treatment of cancer, Parkinson’s disease, cognitive disorders, narcolepsy, female sexual ...

Stock analysts at StockNews.com started coverage on shares of Intra-Cellular Therapies (NASDAQ:ITCI – Get Free Report) in a report released on Thursday. The brokerage set a “hold” rating on the ...

We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) stands ...

Johnson & Johnson’s decision to splash out $14.6 billion on its purchase of Intra-Cellular Therapies earlier this year was largely driven by the acquired company's rising antipsychotic star Caplyta ...

Johnson & Johnson has completed its $14.6 billion acquisition of Bedminster-based neurological drugmaker Intra-Cellular Therapies. The New Brunswick-headquartered pharma giant announced the closing in ...

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced that following the approval of its pending acquisition of Intra-Cellular Therapies, Inc. by Intra-Cellular Therapies ...

Sharon Mates, PhD, is the co-founder and former Chair and CEO of Intra-Cellular Therapies, a CNS-focused biotech that developed the successful drug CAPLYTA ®, acquired by Johnson & Johnson for $14.6 ...